{"id":8158,"date":"2025-07-27T09:07:08","date_gmt":"2025-07-27T06:07:08","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8158"},"modified":"2025-07-27T09:07:08","modified_gmt":"2025-07-27T06:07:08","slug":"solid-biosciences-fda-fast-track-designation-granted-on-july-23-2025-for-sgt-501-a-first-in-class-gene-therapy-for-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/solid-biosciences-fda-fast-track-designation-granted-on-july-23-2025-for-sgt-501-a-first-in-class-gene-therapy-for-catecholaminergic-polymorphic-ventricular-tachycardia-cpvt\/","title":{"rendered":"Solid Biosciences. FDA Fast Track Designation granted on July 23, 2025, for (SGT-501) a first-in-class gene therapy for Catecholaminergic polymorphic ventricular tachycardia (CPVT).\u00a0"},"content":{"rendered":"<div>Solid Biosciences.<\/div>\n<div>FDA Fast Track Designation granted on July 23, 2025, for (SGT-501) a first-in-class gene therapy for Catecholaminergic polymorphic ventricular tachycardia (CPVT).<\/div>\n<div><\/div>\n<div>Key Notes:<\/div>\n<div><\/div>\n<div>1.<span> <\/span>Condition Overview:<\/div>\n<div>Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited heart rhythm disorder that increases the risk of life-threatening ventricular tachycardia (VT) and cardiac arrest.<\/div>\n<div><span> 2. Lack of Current Treatments:<\/span><\/div>\n<div>There are currently no FDA-approved pharmaceutical treatments for CPVT. Management focuses on reducing VT risk using indirect interventions.<\/div>\n<div><span> 3. New Therapy \u2013 SGT-501:<\/span><\/div>\n<div>Solid Biosciences developed SGT-501, a gene therapy that delivers a healthy version of the human cardiac calsequestrin gene directly to heart muscle cells. This targets the genetic cause of CPVT.<\/div>\n<div><span> 4. FDA Support:<\/span><\/div>\n<div><span> \u2022 SGT-501 previously received IND (Investigational New Drug) clearance.<\/span><\/div>\n<div><span> \u2022 In July 2025, it was granted FDA Fast Track Designation, highlighting the urgent need for therapies in this area.<\/span><\/div>\n<div><span> 5. Clinical Trial Plan:<\/span><\/div>\n<div>A first-in-human clinical trial of SGT-501 is scheduled to begin in late 2025.<\/div>\n<div><span> 6. Company Perspective:<\/span><\/div>\n<div>Solid Biosciences emphasized the therapy\u2019s strong preclinical and manufacturing data and sees SGT-501 as a potentially durable and transformative solution for CPVT.<\/div>\n<div><span> 7. Regulatory Advantages:<\/span><\/div>\n<div>Fast Track designation allows:<\/div>\n<div><span> \u2022 More frequent interaction with the FDA<\/span><\/div>\n<div><span> \u2022 Faster feedback and document review<\/span><\/div>\n<div><span> \u2022 Potential for accelerated approval if early results are promising<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-receives-fda-fast-track-designation-sgt-501\">https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-receives-fda-fast-track-designation-sgt-501<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Solid Biosciences. FDA Fast Track Designation granted on July 23, 2025, for (SGT-501) a first-in-class gene therapy for Catecholaminergic polymorphic ventricular tachycardia (CPVT). Key Notes: 1. Condition Overview: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare inherited heart rhythm disorder that increases the risk of life-threatening ventricular tachycardia (VT) and cardiac arrest. 2. Lack of [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8158","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8158"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8158\/revisions"}],"predecessor-version":[{"id":8159,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8158\/revisions\/8159"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}